Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D: Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin - Pablo Mora, MD, MSc, FACE, CDE

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D: Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin - Pablo Mora, MD, MSc, FACE, CDE

Published

March 22, 2018

Created by

CMEducation Resources symposium